These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 11779037)
1. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Wallace MJ; Wiley JL; Martin BR; DeLorenzo RJ Eur J Pharmacol; 2001 Sep; 428(1):51-7. PubMed ID: 11779037 [TBL] [Abstract][Full Text] [Related]
2. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. Blair RE; Deshpande LS; Sombati S; Falenski KW; Martin BR; DeLorenzo RJ J Pharmacol Exp Ther; 2006 Jun; 317(3):1072-8. PubMed ID: 16469864 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Tyler K; Hillard CJ; Greenwood-Van Meerveld B Eur J Pharmacol; 2000 Dec; 409(2):207-11. PubMed ID: 11104836 [TBL] [Abstract][Full Text] [Related]
4. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. Liu Q; Bhat M; Bowen WD; Cheng J J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241 [TBL] [Abstract][Full Text] [Related]
5. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. Smith SR; Terminelli C; Denhardt G J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163 [TBL] [Abstract][Full Text] [Related]
6. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912 [TBL] [Abstract][Full Text] [Related]
7. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. Wallace MJ; Blair RE; Falenski KW; Martin BR; DeLorenzo RJ J Pharmacol Exp Ther; 2003 Oct; 307(1):129-37. PubMed ID: 12954810 [TBL] [Abstract][Full Text] [Related]
8. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat. Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P Neuroscience; 2015 Sep; 303():149-59. PubMed ID: 26135674 [TBL] [Abstract][Full Text] [Related]
9. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. McMahon LR; Koek W Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Gessa GL; Casu MA; Carta G; Mascia MS Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025 [TBL] [Abstract][Full Text] [Related]
11. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Sim-Selley LJ; Martin BR J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230 [TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. McMahon LR Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon LR J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255 [TBL] [Abstract][Full Text] [Related]
15. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Smith SR; Terminelli C; Denhardt G Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577 [TBL] [Abstract][Full Text] [Related]
16. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Wallace MJ; Martin BR; DeLorenzo RJ Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270 [TBL] [Abstract][Full Text] [Related]
17. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Darmani NA Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062 [TBL] [Abstract][Full Text] [Related]
18. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339 [TBL] [Abstract][Full Text] [Related]
19. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417 [TBL] [Abstract][Full Text] [Related]